HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved TREMFYA® ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s disease. The findings demonstrated significant clinical remission and ...

WASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with ...

Tremfya (guselkumab) has received approval from the US Food and Drug Administration (FDA) for paediatric patients with plaque ...

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

J&J (NYSE:JNJ) announced on Tuesday that its FDA-approved antibody therapy, Tremfya, as a subcutaneous option, improved a range of clinical and endoscopic measures in patients with the intestinal ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

Johnson & Johnson JNJ announced that it has submitted a supplemental biologics license application (sBLA) seeking approval of its immunology drug, Tremfya, for a new indication — moderately to ...

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., ...